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The	role	of	the	renin	angiotensin	system	(RAS)	in	atherosclerosis	is	complex	because	of	the	involvement	of	
multiple	peptides	and	receptors.	Renin	is	the	rate-limiting	enzyme	in	the	production	of	all	angiotensin	pep-
tides.	To	determine	the	effects	of	renin	inhibition	on	atherosclerosis,	we	administered	the	novel	renin	inhibi-
tor	aliskiren	over	a	broad	dose	range	to	fat-fed	LDL	receptor–deficient	(Ldlr–/–)	mice.	Renin	inhibition	resulted	
in	striking	reductions	of	atherosclerotic	lesion	size	in	both	the	aortic	arch	and	the	root.	Subsequent	stud-
ies	demonstrated	that	cultured	macrophages	expressed	all	components	of	the	RAS.	To	determine	the	role	of	
macrophage-derived	angiotensin	in	the	development	of	atherosclerosis,	we	transplanted	renin-deficient	bone	
marrow	to	irradiated	Ldlr–/–	mice	and	observed	a	profound	decrease	in	the	size	of	atherosclerotic	lesions.	In	
similar	experiments,	transplantation	of	bone	marrow	deficient	for	angiotensin	II	type	1a	receptors	failed	to	
influence	lesion	development.	We	conclude	that	renin-dependent	angiotensin	production	in	macrophages	
does	not	act	in	an	autocrine/paracrine	manner.	Furthermore,	in	vitro	studies	demonstrated	that	coculture	
with	renin-expressing	macrophages	augmented	monocyte	adhesion	to	endothelial	cells.	Therefore,	although	
previous	work	suggests	that	angiotensin	peptides	have	conflicting	effects	on	atherogenesis,	we	found	that	
renin	inhibition	profoundly	decreased	lesion	development	in	mice.
Introduction
There is evolving complexity in the renin angiotensin system (RAS) 
because of the identification of a spectrum of bioactive angioten-
sin peptides including AngII, AngIII, AngIV, and Ang1-7 (1–3). 
There is also an increasing number of receptors that have been 
recognized to interact with these angiotensin peptides including 
AngII type 1 (AT1) receptors, AT2 receptors, AT4 receptors, and 
mas receptors (4, 5).
AngII has long been considered the major bioactive effector mol-
ecule of the RAS and has been recognized as a major contributor to 
hypercholesterolemia-induced atherosclerosis (6, 7). Chronic infu-
sion of AngII augments the size of atherosclerotic lesions in LDL 
receptor–deficient (Ldlr–/–) and apoE–/– mice (8–11). Conversely, 
pharmacological antagonists of specific components of the RAS 
have decreased the extent of atherosclerosis. Many studies have 
demonstrated that angiotensin-converting enzyme (ACE) inhibi-
tors and AT1 receptor antagonists reduce atherosclerotic lesion 
size (7, 12–15). However, a mechanistic basis for the beneficial 
effects observed with ACE inhibitors and AT1 receptor antagonists 
has not been defined. It is currently unclear whether the efficacy is 
due to inhibition of AngII production, the effect of AngII on AT2 
receptors, or the continued presence of other bioactive angioten-
sin peptides that interact with receptors other than AT1 receptors. 
Renin is not only the rate-limiting enzyme in AngII formation, 
but also shows remarkable substrate specificity for angiotensino-
gen, making it an attractive target for therapeutic inhibition of all 
angiotensin peptides. Thus, renin inhibition may provide a unique 
approach to define the role of angiotensin peptides in the develop-
ment of atherosclerosis.
In addition to the systemic RAS, it has now been recognized that 
several tissues express components of the RAS and possess the 
ability to synthesize AngII (16–20). With regard to atherosclerosis, 
all components of the classical RAS pathway have been identified 
in lesions and are associated predominantly with macrophages (6, 
21–23). The presence of mRNA and protein for RAS components 
has also been detected in cultured macrophages (24–26). Although 
there are several potential sources of angiotensin peptides, the 
relative contribution to lesion formation of systemic versus local 
sources has not been defined.
Recent studies have demonstrated that AT1a receptors have a 
profound effect on atherosclerosis generated by hypercholester-
olemia alone (6, 7) or in combination with AngII infusion (11). 
Angiotensin peptides, particularly AngII, have well-defined effects 
on several cell types present in atherosclerosis. These effects are 
particularly prominent for smooth muscle cells and endothelium, 
with less prominent effects on macrophages (11, 27, 28). To date, 
the contribution of AT1a receptors on specific cell types to the 
atherogenic process has not been determined unequivocally.
The purpose of the current study was to determine whether 
whole-body inhibition of renin decreases atherosclerotic lesion size. 
Furthermore, we determined whether macrophage expression of 
Nonstandard	abbreviations	used: ACE, angiotensin-converting enzyme; AT1 recep-
tor, AngII type 1 receptor; HPF, high-power field; LDLR, LDL receptor; RAS, renin 
angiotensin system.
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renin contributed to the development of atherosclerosis by gener-
ating chimeric mice with renin deficiency in bone marrow–derived 
cells. Finally, we also defined autocrine/paracrine effects of locally 
synthesized angiotensin peptides on AT1a receptors in the develop-
ment of atherosclerosis.
Results
Systemic renin inhibition strikingly reduced atherosclerosis. Aliski-
ren, an octanamide, is the first representative of a new class of 
nonpeptide, low–molecular weight renin inhibitors. Its action 
decreases plasma concentrations of AngII, which causes depres-
sion of negative feedback of renin secretion from the kidney and 
results in increased plasma renin concentrations (29–31). In this 
study, aliskiren was administered at 3 different doses to produce 
increasing systemic inhibition of renin. Aliskiren produced no 
changes in body weight, plasma cholesterol concentrations, 
plasma aldosterone concentrations (Table 1), or lipoprotein-cho-
lesterol distribution (data not shown) in Ldlr–/– mice. The low-
est dose of aliskiren, 2.5 mg/kg/d, gave plasma concentrations 
that were 5-fold higher than the IC50 against 
mouse renin (6.22 ± 2.25 nM), while the 
higher doses of 25 and 50 mg/kg/d gave simi-
lar plasma concentrations that were 100-fold 
above the IC50 (Table 1). All doses of aliskiren 
increased plasma renin concentrations. Renal 
renin mRNA increased in a dose-dependent 
manner (P < 0.0001; Figure 1). Conversely, 
mRNA abundances of angiotensinogen, ACE, 
ACE2, AT1a receptors, and AT2 receptors did 
not change in renal tissue (Supplemental Fig-
ure 1; supplemental material available online 
with this article; doi:10.1172/JCI32970DS1). 
Renin inhibition was further demonstrated 
by the decreased plasma concentrations of 
angiotensin peptides (Figure 2). Infusion of 
2.5 mg/kg/d aliskiren, the lowest dose tested, 
reduced plasma AngII and the sum of angio-
tensin peptide concentrations, while the 
infusion of 25 mg/kg/d led to near ablation 
of all peptides in plasma (Figure 2).
There was a sustained decrease in systolic 
blood pressure during aliskiren infusion at 25 
and 50 mg/kg/d (P < 0.0001; Figure 3). The 
administration of 2.5 mg/kg/d aliskiren did 
not produce an overall statistically signifi-
cant sustained reduction in systolic blood 
pressure, although there was a decrease at 1 interval measured. 
Because we have previously demonstrated that hypercholesterol-
emia caused a mild increase in blood pressure associated with acti-
vation of the RAS (6), we also sought to determine the effect of the 
50-mg/kg/d aliskiren dose on systolic blood pressure in wild-type 
C57BL/6 male mice fed normal laboratory diet. The basal systolic 
blood pressure in these normolipidemic mice was less than that 
in strain-, age-, and gender-matched fat-fed Ldlr–/– mice. Admin-
istration of the highest dose of aliskiren did not change systolic 
blood pressures in normolipidemic C57BL/6 mice, whereas both 
the 25- and 50-mg/kg/d doses reduced systolic blood pressures in 
hypercholesterolemic Ldlr–/– mice to the level observed in normo-
lipidemic C57BL/6 mice (Figure 3).
Atherosclerotic lesion size was measured in both the aortic 
intima by the en face technique and in sections of aortic root. 
Reductions in atherosclerosis were profound in both regions, with 
significant reductions in atherosclerotic lesion size observed in 
mice administered the 2.5-mg/kg/d dose of aliskiren. The 25- and 
50-mg/kg/d doses produced similar results, with near ablation of 
Table 1
Effects of renin inhibition in Ldlr–/– mice fed a fat-supplemented diet for 12 weeks
	 Vehicle	 Aliskiren	 Aliskiren	 Aliskiren	
	 	 (2.5	mg/kg/d)	 (25	mg/kg/d)	 (50	mg/kg/d)
n 15 14 16 6
Body wt (g) 32.3 ± 1.3 28.9 ± 1.4 29.3 ± 0.7 29.9 ± 0.7
Plasma cholesterol (mg/dl) 1,185 ± 93 1,288 ± 109 1,225 ± 129 1,201 ± 102
Plasma aliskiren (μM) 0 0.03 ± 0.005A 0.71 ± 0.23A,B 0.73 ± 0.09A,B
Plasma renin (ng/ml/30 min) 13.8 ± 2.7 31.7 ± 4.5A 31.9 ± 2.9A 33.0 ± 2.9A
Plasma aldosterone (pg/ml) 260 ± 22 330 ± 55 229 ± 24 ND
Values are mean ± SEM. ND, not determined. AP < 0.0001 versus vehicle. BP < 0.0001 versus 2.5 mg/kg/d aliskiren.
Figure 1
Renin inhibition dose-dependently increased renal renin mRNA abundance. Renin mRNA 
abundance (renin/18S rRNA ratio) was quantified by real-time PCR (n = 5 per group). mRNA 
bands by gel electrophoresis are also shown; the lanes were run on the same gel but were 
noncontiguous. Data are mean ± SEM. *P < 0.0001 versus vehicle; #P < 0.0001 versus 
2.5 mg/kg/d aliskiren.
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lesion formation in the aortic arch (Figure 4A). The administration 
of aliskiren also profoundly reduced atherosclerotic lesion size 
throughout the aortic root (vehicle, 0.16 ± 0.02 mm2; 2.5 mg/kg/d, 
0.09 ± 0.01 mm2; 25 mg/kg/d, 0.07 ± 0.01 mm2; 50 mg/kg/d, 
0.05 ± 0.01 mm2; P < 0.0001; Figure 4B). All doses of aliskiren pro-
duced similar reductions in lesion size in this region.
Increased blood pressure is a consistent risk factor for the devel-
opment of atherosclerotic diseases in humans (32). Thus, we 
investigated the association between systolic blood pressure and 
atherosclerotic lesion size in both aortic arch and root in mice 
administered different doses of aliskiren. First, we calculated 
Pearson correlations between systolic blood pressure and (log-
transformed) atherosclerotic lesion size within each of the 4 study 
groups. There were no significant correlations between systolic 
blood pressure and atherosclerotic lesion size in either aortic arch 
or root (data not shown). We also used linear regression to express 
atherosclerotic lesion size in terms of study group assignment and 
systolic blood pressure (Supplemental Figure 2). Even with adjust-
ment for differences in systolic blood pressure, all doses of aliski-
ren still significantly reduced atherosclerotic lesion size in both 
the aortic arch and root (P < 0.001). On the other hand, systolic 
blood pressure did not predict atherosclerotic lesion size once we 
controlled for aliskiren dosage.
Immunostaining of atherosclerotic tissue in aortic roots was 
performed to determine whether reductions in lesion size during 
renin inhibition were accompanied by changes in cell composition. 
Immunostaining of lesions demonstrated that the predominance 
of macrophages in vehicle-infused mice was similar in aliskiren-
infused mice (Figure 4C).
Systemic renin inhibition did not affect specific oxidant mechanisms. 
AngII has previously been shown to promote macrophage expres-
sion of 12/15 lipoxygenase protein, which promotes atheroscle-
rosis in Ldlr–/– mice (33, 34). The abundance of 12/15 lipoxygen-
ase protein was determined in mouse peritoneal macrophages by 
Western blotting. However, we were unable to demonstrate that 
aliskiren administration had any effect on macrophage 12/15 
lipoxygenase expression (data not shown). We also measured 
serum titers of autoantibodies against malondialdehyde-LDL 
(MDA-LDL), which has previously been used as an index of ath-
erosclerosis-related oxidant mechanisms (35). However, serum 
titers of MDA-LDL autoantibodies were unchanged by aliskiren 
administration (data not shown).
Cultured macrophages expressed all components of RAS and synthesized 
the unique precursor angiotensinogen. To determine whether macro-
phages express all components of the classic pathway for angio-
tensin peptide production, RT-PCR was used with primers that 
have annealing sites across intronic boundaries for each pair (36). 
mRNA expression of angiotensinogen, renin, and ACE was detect-
ed in mouse macrophages (Supplemental Figure 3A).
The ability of macrophages to secrete angiotensinogen was inves-
tigated by Western blotting (Supplemental Figure 3B). Mouse plas-
ma protein had 2 specific bands of angiotensinogen at 52 and 64 
kDa, whereas peritoneal macrophage culture medium presented a 
single band at 64 kDa that was highly glycosylated, as reported pre-
viously (36). We have been unable to develop an antibody to detect 
the presence of secreted renin in a Western blotting format.
The deficiency of renin has the potential to upregulate other 
enzymes with similar properties, such as cathepsin D (17). How-
ever, renin deficiency had no effect on cathepsin D mRNA abun-
dance in macrophages (Supplemental Figure 3C).
Renin deficiency in bone marrow–derived cells reduced atherosclerotic lesion 
size unrelated to their AT1a receptors. Because whole-body inhibition of 
renin profoundly decreased atherosclerosis, and because isolated 
macrophages contain all the components for angiotensin peptide 
synthesis including renin, we examined the effect of renin originating 
from bone marrow–derived cells. We used the strategy of irradiating 
Ldlr–/– mice and repopulating with bone marrow–derived cells from 
renin+/+ or renin–/– mice. Although bone marrow has the potential 
to differentiate into many cell types, this procedure predominantly 
repopulates macrophages in atherosclerotic lesions (37).
In Ldlr–/– recipient mice, the renin genotype of bone marrow–
derived cells used to repopulate mice had no influence on body 
weight, wbc counts, plasma cholesterol concentrations, plasma 
concentrations of aldosterone and renin, or systolic blood pres-
sure (Table 2). The chimeric nature of the mice was confirmed 
at the termination of the study by genotyping the bone marrow 
Figure 2
Renin inhibition dose-dependently decreased angiotensin peptide con-
centrations in mouse plasma. Angiotensin peptides in mouse plasma 
were resolved by HPLC and quantified with radioimmunoassay (n = 4 
per group). Data are mean ± SEM. *P < 0.05 versus vehicle; #P < 0.05 
versus 2.5 mg/kg/d aliskiren.
Figure 3
Renin inhibition decreased systolic blood pressure in Ldlr–/– mice. Sys-
tolic blood pressure was measured in Ldlr–/– mice 1 week prior to pump 
implantation and during 2, 4, 8, and 12 weeks of drug administration 
at the indicated doses. Aliskiren was also administered at a dose of 
50 mg/kg/d to normal diet–fed Ldlr+/+ C57BL/6 mice (dotted line). Points 
represent the mean of weekly observations; error bars denote SEM. 
*P < 0.0001 versus vehicle; #P < 0.0001 versus 2.5 mg/kg/d aliskiren.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 118   Number 3   March 2008 987
(Figure 5A). Despite the lack of systemic changes, mice repopu-
lated with cells derived from renin–/– mice had a large reduction in 
atherosclerotic lesion size (Figure 5B). Immunostaining of lesions 
demonstrated that both groups had predominantly macrophage-
rich lesions. Immunostaining for renin was more apparent in 
Ldlr–/– mice repopulated with cells from renin+/+ mice compared 
with cells from renin–/– mice (Figure 5C).
To study a potential oxidant mechanism of macrophage renin 
on atherogenesis, we determined macrophage 12/15 lipoxygenase 
expression. As with the aliskiren studies, we were unable to detect 
an effect of renin deficiency on macrophage 12/15 lipoxygenase 
expression (data not shown). We also determined whether renin 
deficiency in macrophages altered lipid accumulation. Cultured 
peritoneal macrophages from renin+/+ or renin–/– mice were incu-
bated in serum-free DMEM in the presence of acetylated LDL 
(20 μg/ml) for 24 hours. Staining with Oil Red O showed 
intracellular accumulation of neutral lipid in both renin+/+ and 
renin–/– macrophages incubated with acetylated LDL. To quantify 
the cholesterol content in macrophages incubated with acetylated 
LDL, we measured unesterified and esterified cholesterol by gas 
chromatography–mass spectrometric analysis (GC-MS). Renin 
deficiency in mouse macrophages did not result in any change in 
acetylated LDL–induced increases in intracellular unesterified and 
esterified cholesterol (Supplemental Figure 4).
We subsequently defined whether angiotensin peptides gener-
ated by macrophages act primarily in an autocrine/paracrine man-
ner to promote lesion formation. Of the AT1 receptor subtypes, 
only AT1a receptor was detected in macrophages (Figure 6A). 
Therefore, we performed a bone marrow transplantation study 
in which we irradiated Ldlr–/– mice and repopulated them with 
bone marrow–derived cells from AT1a receptor+/+ or AT1a recep-
tor–/– mice. The parameters described for the renin bone marrow 
transplantation studies were also unaffected by the AT1a receptor 
genotype of the bone marrow cells (Table 3). The genotype of the 
peritoneal macrophages at the end of the study confirmed the chi-
meric nature of the mice (Figure 6B). Furthermore, in contrast to 
the profound effects of renin deficiency, we failed to detect any sig-
nificant effect of AT1a receptor genotype of bone marrow–derived 
cells on the size of atherosclerotic lesions (Figure 6C).
Macrophage renin deficiency reduced monocyte adhesion to endothelial 
cells. Because renin deficiency in bone marrow–derived cells decreased 
atherosclerosis unrelated to autocrine effects on macrophage AT1a 
receptors, we studied whether renin expression in macrophages 
would affect adhesion of monocytes to endothelial cells, a pivotal 
process in the initiation and progression of atherosclerosis. Thus, 
we examined THP-1 monocyte adhesion to HUVECs. Initial studies 
demonstrated that AngII (10–7 M for 24 hours) promoted monocyte 
adhesion to endothelial cells (Figure 7A). AngII-induced monocyte 
adhesion to HUVECs was not associated with increased endothelial 
VCAM-1 expression. Although AngII failed to increase VCAM-1 
expression, the ability of HUVECs to express this adhesion mol-
ecule was confirmed by incubation with TNF-α (Supplemental Fig-
ure 5). Antagonism of AngII-induced monocyte adhesion by 10–6 M 
losartan demonstrated the role of AT1 receptors (Figure 7B). Hav-
ing defined the role of AngII to promote adhesion, we coincubated 
confluent endothelial monolayers with peritoneal macrophages 
harvested from either renin+/+ or renin–/– mice that were cultured 
in lower chambers of Transwell plates. Monocyte adhesion was sig-
nificantly increased when HUVECs were coincubated with macro-
phages from renin+/+ mice compared with coincubation with mac-
rophages from renin–/– mice (Figure 7C).
Discussion
Aliskiren effectively inhibits mouse renin and profoundly reduces athero-
sclerosis. The present study demonstrated that renin inhibition 
reduced the size of atherosclerotic lesions in a dose-dependent 
manner in Ldlr–/– mice fed a fat-enriched diet. Renin inhibition 
was achieved by continuous subcutaneous infusion of the novel 
inhibitor aliskiren. Aliskiren is a potent inhibitor of human 
Figure 4
Renin inhibition reduced atherosclerotic lesion development without 
overtly altering cellular composition. (A) Atherosclerotic lesion size was 
measured on the intimal surface of aortic arches. Triangles represent 
individual mice; circles represent the mean; error bars denote SEM. 
*P < 0.0001 versus vehicle; #P < 0.01 versus 2.5 mg/kg/d aliskiren. (B) 
Atherosclerotic lesion size was measured in aortic roots. Data are rep-
resented throughout the aorta root, with transitions between the sinus 
and ascending arch depicted as 0. Filled triangles, PBS vehicle (n = 14); 
filled inverted triangles, 2.5 mg/kg/d aliskiren (n = 14); open triangles, 
25 mg/kg/d aliskiren (n = 15); open inverted triangles, 50 mg/kg/d aliski-
ren (n = 6). Values are mean ± SEM. (C) Examples of atherosclerotic 
lesions immunostained for macrophages and smooth muscle cells. Aor-
tic roots were immunostained using rat anti-mouse CD68 (1:200, left), 
or a rabbit anti–α-SMA (1:200, right). Original magnification, ×200.
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renin and displays species specificity for various isoforms of 
renin (30). The IC50 for aliskiren against mouse renin is 1 order 
of magnitude less effective than on the human enzyme (0.6 nM), 
but greater than its potency against the rat enzyme (80 nM). The 
plasma aliskiren concentrations achieved with doses of drug in 
this study were all above the mouse IC50. Moreover, the function-
al inhibitory effect of aliskiren against mouse renin was demon-
strated by reductions in plasma angiotensin peptide concentra-
tions, with almost complete ablation of angiotensin peptides in 
plasma at higher drug doses.
Because renin conversion of angiotensinogen to AngI is the rate-
limiting step in AngII formation, renin has long been considered 
the optimal target for RAS inhibition. Renin inhibition prevents 
formation of all angiotensin peptides. In contrast, ACE inhibitors 
do not influence non-ACE pathways such as chymase, while AT1 
receptor inhibition increases circulating concentrations of angio-
tensin peptides. In this study, we found that renin inhibition by 
aliskiren strikingly reduced atherosclerosis in mice. This contrasts 
with the effects of AT1a receptor deficiency, which were also pro-
found, but not as efficacious as renin inhibition (6). Also, a survey 
of the literature for both ACE inhibition and AT1 receptor antag-
onists shows consistency with regard to reduced atherosclerotic 
lesion size, but not to the level attained with renin inhibition (7, 
12, 14, 15, 38, 39). However, these differences need to be substanti-
ated by comparing the different modes of RAS inhibition within a 
single study that uses multiple doses.
We have demonstrated previously that hypercholesterolemia 
was associated with increased RAS activity, as indicated by large 
increases in plasma concentrations of angiotensinogen and angio-
tensin peptides (6). In the present study, hypercholesterolemia 
was associated with increased systolic blood pressure. The role of 
angiotensin peptides in this elevation was demonstrated by renin 
inhibition reducing systolic blood pressure to a level observed in 
normolipidemic mice. Thus, there are several indications that 
renin inhibition was achieved with aliskiren to a level that affected 
physiological processes. Effective blockade of the RAS is associat-
ed with increased plasma renin concentrations, as demonstrated 
in the current study. This systemic increase results from release 
of renin in renal juxtaglomerular cells from AngII-induced nega-
tive feedback inhibition. The present results demonstrated that 
such increases in plasma renin concentration during aliskiren 
administration did not modulate the vasculoprotective effect of 
aliskiren. With increased systemic renin concentrations, there is 
the potential to interact with the recently cloned renin/prorenin 
receptor to activate fibrotic pathways (40). However, the relevance 
of high circulating concentrations of renin, and this receptor, to 
atherogenesis is unknown.
Table 2
Effects of renin deficiency in bone marrow–derived cells in 
Ldlr–/– mice fed a fat-supplemented diet for 12 weeks
	 Renin+/+	 Renin–/–
n 12 10
Body wt (g) 32.5 ± 0.7 34.6 ± 0.9
wbc count (103/μl) 8.2 ± 1.0 7.5 ± 0.6
Plasma cholesterol (mg/dl) 1,294 ± 46 1,357 ± 54
Plasma renin (ng/ml/30 min) 12.5 ± 1.8 12.0 ± 1.8
Plasma aldosterone (pg/ml) 274.3 ± 67.5 302.2 ± 91.9
Systolic BP (mmHg) 139 ± 4 137 ± 3
Values are mean ± SEM.
Figure 5
Renin deficiency in bone marrow–derived cells decreased atherosclerosis in Ldlr–/– recipient mice fed a high-fat diet. (A) PCR confirmed the pres-
ence of the disrupted renin gene in bone marrow cells from recipient mice. PCR on bone marrow–derived DNA yielded an amplicon of 265 bp for the 
wild-type renin allele and 386 bp for the disrupted allele. The lanes were run on the same gel but were noncontiguous. (B) Atherosclerotic lesion size 
was measured on aortic arch intimal surfaces. Individual Ldlr–/– recipients are represented by open symbols. Means of each group are represented 
by circles; error bars denote SEM. *P < 0.001 renin+/+ donor (n = 12) versus renin–/– donor (n = 10). (C) Renin deficiency in bone marrow–derived 
cells ablated renin expression in macrophages localized to atherosclerotic lesions in the aortic root. Immunostaining was performed in the athero-
sclerotic lesions of aortic root using rabbit anti-mouse macrophage antisera and a chicken anti-mouse renin IgY. Original magnification, ×200.
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Reductions in atherosclerosis following aliskiren administra-
tion were profound in both vascular regions in which it was mea-
sured, with aortic root lesions having greater reductions than 
those in aortic arches. While higher doses of aliskiren reduced 
systolic blood pressure, reductions in atherosclerosis were 
achieved at doses of aliskiren that showed no persistent changes 
in blood pressure. In addition, we did not find any significant 
correlation between systolic blood pressure and atheroscle-
rotic lesion size after we controlled for aliskiren dosage. Previ-
ously published studies have also demonstrated that AngII-aug-
mented atherosclerosis is not a direct consequence of its ability 
to increase blood pressure. For example, while both AngII and 
norepinephrine increased blood pressure to the same extent in 
apoE–/– mice, only AngII accelerated atherosclerosis (10). Fur-
thermore, the profound decreases in atherosclerotic lesion size 
during administration of AT1 receptor antagonists were not 
observed with either hydralazine or amlodipine when adminis-
tered at doses resulting in equivalent reductions in systolic blood 
pressure (7, 41). Thus, while increased systolic blood pressure is 
frequently associated with atherosclerosis, the stimulus for the 
hypertension appears to be the major determinant of atherogen-
esis rather than pressure per se (42).
AngII is well known to augment specific oxidant pathways 
(43). This has been particularly well documented for the NADPH 
system in smooth muscle cells (43). AngII stimulation of this 
oxidant system has been consistently demonstrated to promote 
smooth muscle cell hypertrophy and hyperplasia (43, 44). How-
ever, NADPH oxidase has a poorly defined role in the develop-
ment of atherosclerosis. Deficiency of p47phox has previously 
been noted to decrease atherosclerotic lesion size in the aortic 
arch, but not the aortic root (45), while no effects were determined 
in another study (46). Furthermore, gp91phox deficiency had no 
effect on atherosclerotic lesion size (47). More emphasis regarding 
atherogenic mechanisms has been placed on extracellular oxidant 
processes that have led to the formation of protein adducts. Spe-
cific subtypes of lipoxygenases have been consistently linked to the 
atherogenic process (48). Previous studies have demonstrated that 
incubation of AngII with mouse peritoneal macrophages and J774 
cells upregulated 12/15 lipoxygenase abundance and activity (33). 
However, we were unable to demonstrate any difference in 12/15 
lipoxygenase activity in macrophages from mice with profound 
renin inhibition. A more general index of oxidant stress has been 
the serum titers of autoantibodies to oxidatively modified pro-
teins. Again, we were unable to detect any difference in the serum 
titers of autoantibodies to one of the most commonly described 
adducts, malondialdehyde. Thus, we were unable to define oxidant 
stress mechanisms that were associated with the profound reduc-
tion in atherosclerosis promoted by renin inhibition.
Deficiency of AT1a receptors has previously been shown to greatly 
decrease atherosclerotic lesion size in hyperlipidemic mice (6, 7). 
Although no direct comparisons have been performed, the relative 
extent of reductions in lesion size in the present study appeared 
larger during renin inhibition than that previously observed in mice 
with AT1a receptor deficiency or pharmacological blockade. Direct 
comparisons of the efficacy of renin inhibition, AT1 receptor block-
ade, and ACE inhibition on reduction in atherosclerotic lesion size 
are complicated by the definition of comparable inhibition for these 
3 different mechanisms. However, the profound reductions in angio-
tensin peptides in this study do obviate the interpretation that the 
reductions in lesion size during AT1a receptor blockade were caused 
Figure 6
AT1a receptor deficiency in bone marrow–derived cells 
did not alter atherosclerotic lesion size. (A) RT-PCR 
confirmed that macrophages expressed mRNA of AT1a 
receptors (AT1aR), but not of AT1b receptors. Examples 
of positive controls (adrenal glands and aorta) and mac-
rophages for AT1a receptors, AT1b receptors, and 18S 
rRNA. Lane 1, adrenal gland; lane 2, aorta; lane 3, mac-
rophages; lane 4, non-RT negative control in adrenal 
glands. The lanes were run on the same gel but were 
noncontiguous. (B) PCR confirmed the presence of 
the disrupted AT1a receptor gene in mouse peritoneal 
macrophages from recipient mice. PCR on macrophage-
derived DNA yielded an amplicon of 650 bp for wild-type 
AT1a receptor and 1.1 kb for the disrupted allele. (C) Ath-
erosclerotic lesion size was measured on aortic arch inti-
mal surfaces. Individual symbols represent Ldlr–/– recipi-
ents. Means of each group are represented by circles; 
error bars denote SEM. n = 25 (AT1a receptor+/+ donor); 
24 (AT1a receptor–/– donor).
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by enhanced stimulation of AT2 receptors (39, 49, 50). Furthermore, 
these data demonstrate the benefit of inhibiting the synthesis of all 
angiotensin peptides on the development of atherosclerosis.
Renin deficiency in bone marrow–derived cells decreases atherosclerosis 
via the inhibition of monocyte adhesion to endothelial cells in the vascular 
wall. The major source of systemic concentrations of renin is the 
renal juxtaglomerular cells. While renin has been detected in several 
extrarenal tissues, it is unclear whether the levels of renin produced 
in extrarenal tissues is sufficient to have biological effects (20). In 
a previous study, we demonstrated that renin protein was detected 
by immunostaining in mouse atherosclerotic lesions (6). However, 
the renin detected in lesions may result from delivery of renin from 
other sources with retention by a receptor-based system (40, 51). 
In the current study, we demonstrated that cultured macrophages 
express a complete RAS, including renin mRNA. Furthermore, the 
creation of chimeric mice with renin deficiency in infiltrating mac-
rophages clearly demonstrated that reductions in atherosclerosis 
could be achieved through deficiency of macrophage-derived renin. 
Importantly, reductions in atherosclerosis were seen in chimeric 
mice repopulated with renin-deficient bone marrow that exhibited 
no changes in plasma renin concentrations, demonstrating a piv-
otal role for macrophage-derived renin in atherosclerosis.
AngII has the potential to interact with many cell types to aug-
ment the atherogenic process. These include endothelial cells, 
smooth muscle cells, and macrophages. One potential mechanism 
by which renin within macrophages could be exerting its effect is the 
autocrine/paracrine effects of generated angiotensin peptides on 
macrophages. Our present results demonstrate that the absence of 
AT1a receptors in bone marrow–derived cells had no effect on lesion 
size in Ldlr–/– mice. This result is consistent with previous studies in 
our laboratory demonstrating that AT1a receptor deficiency in bone 
marrow–derived cells had minimal effects on AngII-induced athero-
sclerosis (11). These results indicate that macrophages are not the 
target cell type for AT1a receptors as a mediator of atherosclerosis.
The initiation and progression of atherosclerotic lesions is associat-
ed with monocyte adhesion to an intact endothelial surface (52, 53). 
Consistent with previous studies (54–57), we found that AngII aug-
mented monocyte adhesion to endothelial cells. This was inhibited 
by incubation of endothelial cells with the AT1 receptor antagonist 
losartan. Monocyte adhesion to endothelial cells stimulated by mac-
rophages from renin+/+ mice was attenuated by macrophages from 
renin–/– mice. These findings are consistent with macrophage-derived 
angiotensin peptides contributing to atherosclerosis via the effects on 
endothelial AT1 receptors. Our studies failed to demonstrate an asso-
ciation of augmented monocyte adhesion with increased endothelial 
VCAM-1 expression. While there has been a previous report of AngII 
increasing VCAM-1 expression in endothelial cells (58), in agree-
ment with the present study, others have also failed to demonstrate 
increased VCAM-1 (55–57, 59). Thus, the in vitro data are consistent 
with AngII facilitating monocyte adhesion, although the regulator 
of this effect has not been identified. Because endothelial cells pos-
sess AT1a receptors and the function of this cell type regulates lesion 
development, future in vivo studies are needed to explore this axis 
using AT1a receptor–floxed mice.
In conclusion, renin inhibition profoundly decreased formation 
of atherosclerosis. Importantly, reductions in atherosclerosis were 
evident in Ldlr–/– mice with deficiency of renin in bone marrow–
derived cells, invoking a prominent role for macrophage-derived 
renin in atherosclerosis.
Methods
Mice and diet
Ldlr–/– (B6.129S7-Ldlrtm1Her, stock no. 002207), AT1a receptor–/– (B6.129P2-
Agtr1atm1Unc, stock no. 002682), and age-matched C57BL/6 male mice 
(stock no. 000664) were obtained from The Jackson Laboratory. Male 
renin–/– mice on a C57BL/6 background (N9) were generated as previ-
ously described (60). LDLR and AT1a receptor genotypes were deter-
mined by PCR as described previously (6). Renin genotyping used the 
Table 3
Effects of AT1a receptor deficiency in bone marrow–derived cells 
in Ldlr–/– mice fed a fat-supplemented diet for 12 weeks
	 AT1a	receptor+/+	 AT1a	receptor–/–
n 25 24
Body wt (g) 28.0 ± 0.9 29.2 ± 0.7
wbc count (103/μl) 11.4 ± 0.5 10.5 ± 0.8
Plasma cholesterol (mg/dl) 621 ± 43 671 ± 33
Plasma renin (ng/ml/30 min) 19.8 ± 5.1 27.4 ± 4.8
Values are mean ± SEM.
Figure 7
Renin deficiency in mouse macrophages markedly reduced monocyte 
adhesion to endothelial cells. (A) AngII resulted in increased THP-1 
monocyte adhesion to endothelial cells. The adhesion assay was per-
formed by coincubation of 10–7 M AngII with HUVECs for 18 hours. Val-
ues (mean ± SEM) represent cell number of each well relative to vehicle 
per HPF (n = 4 per group). *P = 0.009 versus vehicle. (B) The AT1 
receptor antagonist losartan inhibited AngII-induced THP-1 monocyte 
adhesion to endothelial cells. The adhesion assay was performed by 
coincubation of 10–7 M AngII and 10–6 M losartan. Losartan was added 
2 hours prior to the addition of AngII to cultured HUVECs. Values (mean 
± SEM) represent cell number of each well relative to losartan per HPF 
(n = 3 per group). *P < 0.001 versus AngII. (C) Renin deficiency resulted 
in decreased THP-1 monocyte adhesion to HUVECs. Cultured perito-
neal macrophages from renin+/+ or renin–/– mice were coincubated with 
HUVECs for 24 hours, and an adhesion assay was then performed. 
Values (mean ± SEM) represent cell number of each well relative to 
renin–/– per HPF (n = 4 per group). *P = 0.03 versus renin+/+.
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following primers: 5′-ACTCTTGTTGCTCTGGAGTCCTT-3′, 5′-AGTAG-
TAGAAGGGGGAGTTGTGG-3′, 5′-GCTACCCGTGATATTGCTGAA-3′, 
and 5′-CTTCCCAAAGCTGGCTTATTC-3′. The resultant wild-type and 
deficient allele bands were 265 and 386 bp, respectively. All mice were back-
crossed 10 times into a C57BL/6 background. Littermates were selected for 
the studies reported in this manuscript.
All mice were maintained in a barrier facility and fed normal mouse 
laboratory diet. To induce hypercholesterolemia, mice were changed to 
a diet supplemented with saturated fat (milk fat 21% wt/wt) and choles-
terol (0.15% wt/wt, diet no. TD88137; Harlan Teklad). All studies were 
performed with the approval of the University of Kentucky Institutional 
Animal Care and Use Committee.
Aliskiren administration
Model 2004 Alzet mini-osmotic pumps (Durect Corp.) were implanted into 
male Ldlr–/– or C57BL/6 mice at the age of 6–8 weeks. Pumps were filled with 
either PBS (n = 15) or solutions of aliskiren dissolved in PBS (2.5 mg/kg/d, 
n = 14; 25 mg/kg/d, n = 16; 50 mg/kg/d, n = 6) and replaced at 28-day intervals 
to continuously deliver solutions for a total of 12 weeks in Ldlr–/– mice (8, 9). 
Aliskiren (50 mg/kg/d) was infused for 4 weeks in C57BL/6 mice (n = 8).
Irradiation and bone marrow repopulation
This procedure was performed as described previously (11). Bone marrow 
was harvested from renin+/+ or renin–/– and AT1a receptor+/+ or AT1a recep-
tor–/– male mice (6–8 weeks old) and injected (1 × 107 cells/mouse) into 
age-matched male Ldlr–/– recipient mice that had been irradiated. Four 
weeks after bone marrow repopulation, recipient mice were changed to a 
diet supplemented with fat for 12 weeks.
Systolic blood pressure measurements
Systolic blood pressure was measured using the Visitech tail cuff system 
(BP-2000 Visitech Systems) as described previously (38, 61). Systolic blood 
pressure measurements were performed 1 week before osmotic pump 
implantation and 2, 4, 8, and 12 weeks after implantation or 4, 8, and 12 
weeks after bone marrow transplantation.
Measurement of plasma components
Lipid. Plasma cholesterol concentrations and lipoprotein cholesterol distri-
butions were determined as described previously (9).
RAS. Concentrations of angiotensin peptides were determined by resolv-
ing plasma by HPLC and performing a radioimmunoassay on the fractions 
as described previously (62). Plasma renin and aldosterone concentrations 
were measured as described previously (6). For determination of the IC50 
for aliskiren, plasma (8 μl) from 3-month fat-fed Ldlr–/– mice (n = 3) was 
incubated with an excess of rat angiotensinogen in the absence and pres-
ence of aliskiren (0.01–100 nM) for 30 minutes at 37°C. AngI was mea-
sured by radioimmunoassay (Diagnostic Systems Laboratories).
Aliskiren concentration. Plasma concentrations of aliskiren were measured 
by liquid chromatography/mass spectrometry as described previously (63).
Oxidation autoantibody titers. Serum autoantibodies to MDA-LDL were 
measured by ELISA as described previously (64).
Atherosclerosis quantification
Atherosclerosis was quantified both on the aortic intima of the arch and in 
the root as described previously (65, 66).
Cholesterol content in macrophages
Resident mouse peritoneal macrophages were obtained from male renin+/+ 
or renin–/– mice (6–8 weeks old) as described previously (67). Cells were 
incubated with DMEM supplemented with 10% vol/vol FBS and antibiot-
ics (penicillin G, 100 IU/ml, and streptomycin, 100 μg/ml) overnight. Cells 
were washed with serum-free DMEM to remove nonadherent cells, and 
monolayers were incubated in serum-free DMEM in the presence of acety-
lated LDL (20 μg/ml; Intracel) for 24 hours. Macrophages were extracted 
with chloroform/methanol at a 2:1 ratio with 5α-cholestane added as an 
internal standard. Lipid extracts were dissolved in methylene chloride. 
Unesterified cholesterol was quantified by GC-MS using a CP-3800 gas 
chromatograph and a Saturn 2200 mass spectrometry (Varian) equipped 
with a DB-5 MS column (J & W Scientific Inc.). Saponification was per-
formed to determine total cholesterol. Cholesterol measurements were 
normalized to cellular protein.
mRNA abundance of RAS components
RNA was harvested from mouse tissues and peritoneal macrophages using 
the SV Total RNA Isolation System (Promega). RT-PCR or real-time PCR 
was performed as described previously (6, 36). mRNA abundances were 
calculated with normalization to either 18S rRNA or β-actin. Nontemplate 
and non-RT reactions were used as negative controls.
Immunostaining
Macrophages were detected using rat anti-mouse CD68 (FA-11, catalog 
no. MCA 1957; Serotec) or rabbit anti-mouse macrophage serum (catalog 
no. AIA31240; Accurate Chemical Company) as described previously (6). 
Smooth muscle cells and endothelial cells were detected using rabbit anti–
α-SMA (catalog no. ab5694; Abcam) and biotin-conjugated rat anti-mouse 
CD31 monoclonal antibody (PECAM-1, catalog no. 553371; BD Biosciences 
— Pharmingen), respectively. Immunostaining was performed on frozen sec-
tions, with appropriate negative controls, as described previously (64, 68).
Adhesion assay
HUVECs were isolated from human umbilical cords obtained from the Uni-
versity of Kentucky Labor and Delivery unit and cultured in M199 media 
supplemented with 20% FBS as described previously (69). Passages 1–5 were 
grown to confluence in cell culture inserts coated with human fibronectin 
(catalog no. 354492; BD). Plates were washed with PBS, and monolayers 
were incubated in M199 media with FBS (1% vol/vol) overnight. Cells were 
incubated for 24 hours with AngII (10–7 M), losartan (10–6 M), or peritoneal 
macrophages from renin+/+ or renin–/– mice placed in the lower chamber. 
Adhesion assays were performed as described by Huber et al. (70).	Briefly, 
THP-1 cells were stimulated by TNF-α (10 ng/ml) and then labeled with 
calcein AM (catalog no. C-3099; Invitrogen). Labeled cells (5 × 104 /well) 
were added to the upper chamber of each well. After incubating for 30 min-
utes at 37°C, unbound cells were washed off, and bound THP-1 cells were 
fixed with glutaraldehyde (1% wt/vol). Bound monocytes were counted by 
an inverted phase-contrast microscope. A minimum of 4 high-power fields 
(HPFs) of each well were counted by at least 2 observers that were blinded to 
the experimental design. The percent adhesion was calculated as the mean 
cell number of each well relative to the mean cell number of vehicle.
Western blotting analyses
Western blotting analyses of angiotensinogen in plasma and cultured mac-
rophage medium, and 12/15 lipoxygenase in macrophages were performed 
as described previously (6, 71). Western blotting of VCAM-1 in cultured 
HUVECs was performed using mouse anti-human CD106 (catalog no. 
555645; BD Biosciences — Pharmingen).
Statistics
To compare 2 groups on a continuous response variable, we used a 2-sam-
ple t test. To compare more than 2 groups on a continuous response vari-
able, we used 1-way ANOVA; however, if the assumptions for the ANOVA 
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were not satisfied, we either performed the ANOVA on log-transformed 
values or used the Kruskal-Wallis procedure. For repeated-measures data, 
we fitted an appropriate linear mixed model. Relationships between sys-
tolic blood pressure and atherosclerotic lesion size were analyzed using 
Pearson correlations and linear regression models. A P value less than 0.05 
was considered statistically significant. Data are presented as mean ± SEM. 
SAS version 9.1 (SAS Institute) was used to carry out data analyses.
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